home All News open_in_new Full Article

Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st

SHANGHAI, April 25, 2025 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental new drug application (“NDA”) for toripalimab (trade name: TUOYI®) as the first-line treatment for unresectable or metastatic melanoma […]


today 7 h. ago attach_file Other

attach_file Society
attach_file Economics
attach_file Other
attach_file Science
attach_file Society
attach_file Other
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Other
attach_file Events
attach_file Economics
attach_file Culture
attach_file Economics
attach_file Politics
attach_file Culture
attach_file Society
attach_file Economics
attach_file Events
attach_file Other


ID: 2480712942
Add Watch Country

arrow_drop_down